| Literature DB >> 29731905 |
Zhoujun Cui1, Hongbo Li1, Feng Liang1, Cuiling Mu1, Yuhua Mu1, Xuegong Zhang1, Jundong Liu1.
Abstract
WD repeat domain 5 (WDR5) serves an important role in various biological functions through the epigenetic regulation of gene transcription. Aberrant expression of WDR5 has been observed in various types of human cancer, including prostate cancer, breast cancer and leukemia. However, the role of WDR5 expression and its clinical implications in hepatocellular carcinoma (HCC) remain largely unknown. The present study investigated the WDR5 expression pattern in HCC. It was demonstrated that the mRNA and protein levels of WDR5 were upregulated in HCC cancer tissues compared with normal adjacent tissues using reverse transcription-quantitative polymerase chain reaction and western blotting. Furthermore, the elevated WDR5 protein level was significantly associated with the histological grade (P=0.038), tumor size (P=0.023), tumor-node-metastasis stage (P=0.035) and reduced long-term survival time. Additionally, it was demonstrated through the shRNA-mediated knockdown of WDR5 in HCC cells in vitro that WDR5 expression promotes cell proliferation using an MTT assay. Taken together, the results suggested that WDR5 overexpression may have an oncogenic effect in HCC, and may be a promising biomarker for the diagnosis and prognosis of HCC.Entities:
Keywords: WD repeat domain 5; hepatocellular carcinoma; histone H3 lysine 4; prognosis; short hairpin RNA
Year: 2018 PMID: 29731905 PMCID: PMC5921231 DOI: 10.3892/ol.2018.8298
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Associations between WDR5 tumor expression and clinicopathological parameters.
| WDR5 expression | ||||
|---|---|---|---|---|
| Variable | Cases, n | High | Low | P-value |
| Sex | NS | |||
| Male | 62 | 40 | 22 | |
| Female | 51 | 39 | 12 | |
| Age (years) | NS | |||
| ≥50 | 65 | 44 | 21 | |
| <50 | 48 | 35 | 13 | |
| AFP (ng/ml) | NS | |||
| >400 | 52 | 38 | 14 | |
| ≤400 | 61 | 41 | 20 | |
| HBsAg | NS | |||
| Negative | 54 | 37 | 17 | |
| Positive | 59 | 42 | 17 | |
| Liver cirrhosis | NS | |||
| No | 45 | 34 | 11 | |
| Yes | 68 | 45 | 23 | |
| Histological grade | 0.038 | |||
| Well/moderate | 53 | 32 | 21 | |
| Poor | 60 | 47 | 13 | |
| Tumor size | 0.023 | |||
| ≥5 | 58 | 35 | 23 | |
| <5 | 55 | 44 | 11 | |
| TNM stage | 0.035 | |||
| I–II | 56 | 34 | 22 | |
| III–IV | 57 | 45 | 12 | |
WDR5, WD repeat domain 5; NS, not significant; AFP, α-fetoprotein; HBsAg, hepatitis B surface antigen; TNM, tumor-node-metastasis.
Figure 1.Significantly elevated WDR5 expression levels in HCC tumor tissue compared with adjacent non-tumor tissue. (A) Reverse transcription-quantitative polymerase chain reaction and (B) western blotting were used to analyze WDR5 expression in the tumor and adjacent samples. (C) Percentages of HCC tissues and adjacent non-tumor tissues high and low WDR5 expression. Immunohistochemistry was used to analyze the WDR5 expression in (D) adjacent and (E) tumor tissue (magnification, ×200). Statistical analysis was performed with Student's t-test. **P<0.01. WDR5, WD repeat domain 5; HCC, hepatocellular carcinoma.
Figure 2.WDR5 expression was significantly elevated in HCC cell lines. (A) Reverse transcription-quantitative polymerase chain reaction was used to analyze WDR5 expression in HCC cell lines and a normal liver cell line. (B) Western blotting was used to analyze WDR5 expression in HCC cell lines and a normal liver cell line. *P<0.05, **P<0.01 vs. HL7702. (C) shRNA transfection was used to downregulate WDR5 expression in HCC cell lines. **P<0.01 vs. untransfected group. Statistical analysis was performed with one-way analysis of variance and Tukey's test. WDR5, WD repeat domain 5; HCC, hepatocellular carcinoma; shRNA, short hairpin RNA; NS, not significant.
Figure 3.WDR5 expression promotes HCC cell proliferation in vitro. (A) MTT assay to analyze the proliferation rate of HCC cell lines and a normal liver cell line. **P<0.01, ***P<0.001 vs. HL7702. (B) MTT assay to analyze the proliferation rate of the SNU-449 cell line transfected with non-targeting or WDR5-specific shRNA. (C) MTT assay to analyze the proliferation rate of the MHCC97H cell line transfected with non-targeting or WDR5-specific shRNA. ***P<0.001 vs. untransfected group. Statistical analysis was performed with one-way analysis of variance and Tukey's test. WDR5, WD repeat domain 5; HCC, hepatocellular carcinoma; shRNA, short hairpin RNA; NS, not significant.
Figure 4.The overall survival rates of the 113 HCC patients were compared in the high-WDR5 and low-WDR5 expression groups. Statistical significance was determined using the log-rank test. HCC, hepatocellular carcinoma; WDR5, WD repeat domain 5.
Univariate and multivariate analyses of factors associated with overall survival.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
| Variables | HR | 95% CI | P-value | HR | 95% CI | P-value |
| WDR5 (high vs. low) | 2.151 | 1.141–4.058 | 0.018 | 2.239 | 1.167–4.296 | 0.015 |
| Sex (male vs. female) | 1.663 | 0.795–3.479 | 0.177 | – | – | – |
| Age (≥50 vs. <50) | 1.755 | 0.850–3.625 | 0.129 | – | – | – |
| AFP (ng/ml; ≥400 vs. <400) | 1.948 | 0.977–3.887 | 0.058 | – | – | – |
| HBsAg (negative vs. positive) | 1.846 | 0.904–3.766 | 0.092 | – | – | – |
| Liver cirrhosis (no vs. yes) | 1.882 | 0.933–3.795 | 0.077 | – | – | – |
| Histological grade (well/moderate vs. poor) | 1.921 | 1.014–3.640 | 0.045 | 1.946 | 1.032–3.671 | 0.040 |
| Tumor size (≥5 vs. <5) | 2.066 | 1.081–3.948 | 0.028 | 2.081 | 1.094–3.959 | 0.026 |
| TNM stage (I–II vs. III–IV) | 2.053 | 1.070–3.942 | 0.031 | 2.007 | 1.046–3.851 | 0.036 |
WDR5, WD repeat domain 5; HR, hazard ratio; CI, confidence interval; AFP, α-fetoprotein; HBsAg, hepatitis B surface antigen; TNM, tumor-node-metastasis.